Previous Article | Next Article 
Journal of Virology, December 1999, p. 10399-10405, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
The Hepatitis B Virus X Protein Transactivates
Viral Core Gene Expression In Vivo
Kurt
Reifenberg,1
Heike
Wilts,1
Jürgen
Löhler,2
Petra
Nusser,1
Ralph
Hanano,3
Luca G.
Guidotti,4
Francis V.
Chisari,4 and
Hans-Jürgen
Schlicht5,*
Laboratory Animal Research
Unit,1 Department of
Immunology,3 and Department of
Virology,5 University of Ulm, 89081 Ulm, and
Heinrich Pette Institute for Experimental Virology and
Immunology, 20251 Hamburg,2 Germany, and
Division of Experimental Pathology, Scripps Research Institute,
La Jolla, California 920374
Received 2 September 1999/Accepted 7 September 1999
 |
ABSTRACT |
The function of the X protein in the life cycle of mammalian
hepadnaviruses is unclear. Based on tissue culture experiments it has
been suggested that this protein represents a transcriptional transactivator which might be essential for the expression of the viral
core gene. Here we have examined whether the activity of the human
hepatitis B virus (HBV) core gene in vivo depends on X coexpression. To
this end we compared core gene expression between four lineages of
transgenic mice carrying the HBV core gene in cis
arrangement with the X gene (cex lineage) and six lineages containing a
modified construct in which the start codon of the X gene had been
deleted (ce lineage). Whereas all cex lineages consistently exhibited a
high-level hepatic core gene expression, the liver-specific core gene
expression pattern of the ce lineages was heterogenous with four
lineages virtually not expressing the core gene. This defect was due to
a strongly reduced transcription since no core mRNA could be detected
by Northern blotting. To test whether core gene expression could be
restored by providing an intact X gene in trans, we
crossbred mice of two lines which expressed no core mRNA or core
protein with transgenic mice expressing the X-gene product under the
transcriptional regulation of the liver-specific major-urinary-protein
promoter/enhancer (MUP-X mice). The introduction of the MUP-X transgene
induced core mRNA expression and core protein biosynthesis in the
livers of the double-transgenic mice. This demonstrates that the X-gene
product has the capacity to transactivate HBV core gene expression in vivo.
 |
INTRODUCTION |
The hepadnaviruses comprise a small
group of enveloped DNA viruses which are characterized by extreme
species and organ specificity (6). The most prominent
members of this virus group are the human hepatitis B virus (HBV), the
woodchuck hepatitis virus (WHV), the ground squirrel hepatitis virus,
and the duck hepatitis virus. Whereas the genomes of all hepadnaviruses
comprise three open reading frames (ORFs) encoding the core, envelope,
and polymerase proteins, mammalian hepadnaviruses possess an
additional, fourth, ORF. This ORF was designated X since its function
remained unclear. As was shown in the WHV (5) and HBV
(16, 19, 25) systems, the X-gene product (pX) is expressed
at least during certain stages of hepadnaviral infection.
Since the position of the X ORF within the hepadnavirus genome
resembled the locations of the Tat and Tax ORFs in the human immunodeficiency virus and human T-cell leukemia virus genomes, it was
suggested that pX might represent a transcriptional transactivator (17). Later it could be shown in a variety of tissue culture systems that pX does in fact have transactivating properties
(4, 24, 29; for a review, see reference
22). In contrast to retroviral transactivators which
specifically exert their function on the viral long terminal repeat
element, however, pX was found to transactivate a wide variety of
cellular and viral genes.
In spite of these findings, the precise function of pX during the viral
life cycle remained unknown. X-defective hepadnaviral genomes are
replication competent after transfection into differentiated hepatoma
cell lines (2, 14, 26). On the other hand, studies performed
in the WHV system unequivocally demonstrated that an intact X gene is
required for the successful establishment of hepadnavirus infection in
vivo (3, 31). Although these studies proved that pX exerts
an essential function during the hepadnavirus life cycle, they did not
identify what this function was. Because of the known transactivating
potential of pX, it was suggested that the lack of infectivity of the
X-gene mutants was due to a defect in viral gene expression. In this
respect, regulation of the core gene promoter appeared to be a
particularly interesting potential target for pX since this promoter is
preferentially active in hepatocytes and is believed to contribute to
the liver tropism of the hepadnaviruses (1, 9, 12, 28, 30).
The aim of the present study was to examine the transactivating
potential of the X-gene product on the HBV core gene in an in vivo
situation. As has been pointed out, expression of hepadnavirus genes
after transfection of cloned viral DNA into tissue culture cells is
mostly pX independent. For this reason, the suitability of such in
vitro systems for the analysis of pX function is questionable. We
therefore decided to analyze the transactivating properties of this
protein in transgenic mice, which more closely approximate the
situation encountered in a normal infection.
Recently, we have generated four lineages of transgenic mice carrying
the HBV core and X genes in cis arrangement (cex lineages [20]). These mice expressed the X mRNA in all organs
investigated and exhibited a high-level HBV core protein expression in
the liver. To investigate the role of pX for HBV core gene expression, we generated six additional mouse lineages which carried the same transgene as the cex mice except that the start codon of the X gene was
deleted (ce lineages). In four of these lineages virtually no
hepatocellular core gene expression could be detected, suggesting an
impairment of HBV core gene activity due to the lack of X coexpression. Here we tested whether core gene expression could be restored in these
mice by introducing a functional X gene in trans. To this
end, we crossbred mice from two core-negative ce lines with mice of
transgenic lineages expressing the X gene under the transcriptional regulation of the major-urinary-protein (MUP) promoter (8). Our data indicate that pX has the capacity to transactivate HBV core
gene expression in vivo and support the hypothesis that the biological
function of pX may be the transcriptional transactivation of the core gene.
 |
MATERIALS AND METHODS |
Generation of transgenic mice.
Animals were bred at the
Animal Research Unit of the University of Ulm under strict
specific-pathogen-free conditions. All analyses presented in this
report were performed with hemizygous animals.
Production and characteristics of cex-transgenic mice coexpressing the
HBV core and X genes (ayw subtype) under authentic promoter control and
MUP-X-757- and MUP-X-760-transgenic mice (expressing the X gene under
control of the MUP promoter/enhancer) have been described (8,
20). In previous works (20, 21) lineages cex-1, cex-2,
cex-4, and cex-5 had been designated cexL, cexC, cexIV, and cexV,
respectively. For production of ce-transgenic lineages, plasmid
p24.6/29, which had been used previously for generation of the cex
mice, was cut with NcoI, and the single-stranded protruding
ends containing the start codon of the X gene were removed by treatment
with mung bean nuclease. This mutation has already been used in
previous studies (4) to prevent the expression of a
functional X-gene product. After religation and removal of vector
sequences, the HBV fragment was microinjected into C57BL/6J (B6) or
F2(B6 × CBA/Ca) (F2) embryos according to standard
procedures. Two of the six ce-transgenic lineages, designated ce-1 and
ce-2, were directly obtained on a B6 background, whereas the other
lineages were derived from F2 founders and backcrossed to the B6 strain for at least three generations before expression analysis. Cex- and
ce-transgenic animals were identified by PCR amplification of
transgenic sequences using primers GAG ATG GGG TTA CTC TCT and CCT TGT
AAG TTG GCG AGA or in few experiments by detection of hepatitis B e
antigen (HBeAg) in the serum using a commercially available diagnostic
test kit (HBe or HBe II; Abbott, Wiesbaden, Germany). MUP-X-transgenic
mice were identified by PCR amplification of transgene-specific
sequences using the MUP-promoter-specific plus primer TGT AGC CAC GAT
CAC AAG AA and the X-specific minus primer GGT GAA GCG AAG TGC ACA.
Transgene copy number.
Genomic DNA was prepared from
representatives of all cex and ce lineages and was dot blotted onto
nylon membranes. DNA was equilibrated using a
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-specific
32P-labelled probe. For determination of transgene copy
number the membranes were hybridized with an HBV-specific probe.
Single-copy integrations were verified by selective PCR analysis as
described previously (20).
Northern blotting.
For Northern blotting, snap-frozen organs
were pulverized in liquid nitrogen in a microdismembrator (Braun
Biotech International GmbH, Melsungen, Germany), and total RNA was
prepared using the RNEasy Midi Kit (Qiagen). Twenty-five micrograms of
total RNA was separated on a formaldehyde gel, blotted onto nylon
membranes, and hybridized either with an HBV core (BglII
fragment of the core ORF)- or a GAPDH-specific 32P-labelled probe.
Quantitation of HBcAg.
For quantitation of hepatitis B core
antigen (HBcAg) in murine organs, the Abbott IMX microparticle HBe
assay system, which detects both HBeAg and HBcAg (20), was
used. The test was calibrated with recombinant HBcAg prepared from
Escherichia coli. For analysis, 10 mg of snap-frozen
pulverized tissue was suspended in TNE containing 1% Triton X-100
which was then diluted such that the HBcAg concentration fell within
the range of the calibration curve.
Immunohistology.
Tissue specimens were fixed in 4%
formaldehyde solution in phosphate-buffered saline (pH 7.2).
HBcAg-specific immunostaining was performed with paraffin sections
using the avidin-biotin complex method (11). Paraffin
sections were treated with a commercial target unmasking fluid
(Dianova, Hamburg, Germany) in a microwave oven before antibody
incubation. The sections were incubated overnight at 4°C with a
1:4,000-diluted polyclonal rabbit antiserum specific for both HBcAg and
HBeAg (23). Specifically bound antibodies were detected with
a biotinylated secondary antibody and subsequent incubation with
phosphatase-conjugated streptavidin (Biogenex, San Ramon, Calif.)
and staining with naphthol AS-BI phosphate in combination with
hexazotized new fuchsine (E. Merck AG, Darmstadt, Germany).
Alternatively, phosphatase activity was revealed using a commercial
5-bromo-4-chloro-3-indolylphosphate (BCIP)-nitroblue tetrazolium
substrate solution (DAKO Diagnostika, Hamburg, Germany). Endogenous
avidin-binding activity was reduced by pretreatment of the sections
with avidin and biotin solutions (Zymed Laboratories, San Francisco,
Calif.). Negative controls comprised naive rabbit serum and tissues
from nontransgenic mice.
Sequence analysis.
To investigate for the presence of an
intact translational start codon of the X gene in cex mice and for the
absence of this ATG codon in ce mice, total liver RNA was obtained from
representatives of all lineages as mentioned above. The RNA was treated
with DNase I (amplification grade; Life Technologies, Paisley,
Scotland) and was reverse transcribed with primer AAG GAT CCG TCG ACA
TCG ATA ATA CGA CTC ACT ATA GGG ATT TTT TTT TTT TTT TTT using the SuperScript II reverse transcription kit (Life Technologies). The
resulting liver-specific cDNAs as well as samples of leukocytic genomic
DNA were amplified using the plus primer GAT CCA TAC TGC GGA ACT, which
anneals downstream from the initiation site of X-gene transcription
(27), and the minus primer CCC GCG CAG GAT CCA GTT, which
anneals shortly downstream from the translational start signal of the X
ORF. In order to investigate the integrity of the core gene promoter in
transgenic mice, leukocytic DNA was amplified using primer GGG AAG CTT
GGG TAT ACA TTT AAA CCC, which anneals to the 5' terminus of the cex
and ce constructs, and primer GGG AAG CTT GAG TAA CTC CAC AGT AGC,
which anneals shortly downstream from the translational start signal of
the c-ORF. Sequence analyses of cloned amplification products were
performed by MWG Biotech (Ebersberg, Germany).
 |
RESULTS |
Impairment of core gene expression in transgenic livers by X-gene
inactivation.
Recently, we have generated four lineages
(designated cex lines) of transgenic mice carrying the HBV core ORF
with all upstream regulatory elements known to be relevant for core
gene expression together with an intact X gene (Fig.
1, construct cex) (20). These
mice expressed high levels of both HBc and HBe protein. To investigate
whether pX was required for core gene expression, the start codon of
the X gene was deleted as described in the methods section (Fig. 1,
construct ce). Since the X ATG does not overlap with any regulatory
element of the HBV core gene, its deletion should not influence core
gene expression directly. On the other hand, this mutation was
previously shown to prevent the expression of a functional X-gene
product (4).

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 1.
DNA constructs used for the generation of transgenic
mice. The construct used for generation of cex-transgenic mice
(20) comprised a fragment of the HBV genome containing the
core ORF (HBc/e), the core promoter (Pc/e), and the enhancer elements
(Enh-I and Enh-II). Since the X gene colocalizes with these sequences,
the cex construct carried a functional X gene. Px, X promoter; HBx,
X-ORF; p(A), polyadenylation signal. To provide a functional p(A) site
for the core gene, a short HBV sequence including the authentic HBV
p(A) signal was added downstream of this fragment. The construct, used
for the generation of ce-transgenic mice, was obtained by deleting the
translational start codon of the X gene (indicated by the vertical
arrow) in the cex construct. In MUP-X-transgenic mice (8)
the X gene was regulated by the liver-specific promoter/enhancer
complex of the MUP gene. ORFs and transcriptional regulatory elements
are depicted as boxes. The mRNA species expected to be expressed by the
various DNA constructs are presented as horizontal arrows. The relevant
translational start codons are indicated by black dots. Core gene
transcription of cex- and ce-transgenic mice should result in the
expression of a 1.5-kb transcript.
|
|
Upon microinjection of the X-defective construct into murine zygotes,
six transgenic lineages were established and designated
as ce lineages.
Using dot blot analysis of genomic DNA, the transgene
copy numbers of
all cex and ce lineages were determined (cex-1,
1 copy; cex-2, 1 copy;
cex-4, approximately 5 copies; cex-5, approximately
10 copies; ce-1, 1 copy; ce-2, approximately 10 copies; ce-5,
approximately 100 copies;
ce-8, 1 copy; ce-9, approximately 10
copies; ce-10, approximately 10 copies). The presence of the translational
start codon of the X gene in
cex lineages and the absence of this
ATG in ce lineages, respectively,
was confirmed in representatives
of all lines by sequence analyses of
PCR products amplified from
genomic DNA and from liver-specific cDNA,
respectively (data not
shown). To investigate whether X-gene
inactivation affected core
gene expression, we first compared the HBcAg
concentrations in
the livers of X-positive cex mice and X-negative ce
mice. As is
depicted in the left diagram of Fig.
2A, a high-level HBcAg expression
could
be observed in the livers of all cex mice which carried
the intact X
gene. In contrast, the ce lineages exhibited a heterogenous
hepatic
core gene expression pattern. Whereas the livers of ce-1
and ce-8
transgenic mice exhibited respectively high and low levels
of HBcAg
expression, virtually no HBcAg was detectable in livers
from four of
the six X-defective lineages (Fig.
2A, right, ce-2,
ce-5, ce-9, and
ce-10). The hepatic HBcAg expressions of X-positive
cex lineages and
X-negative ce lineages were found to differ significantly
(as
determined by analysis of variance,
P < 0.05).

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 2.
HBc/eAg expression in organs of X-positive cex- and
X-negative ce-transgenic mice. Mean HBcAg concentrations were
quantitated in livers (A) and kidneys (B) of transgenic mice
originating from four cex lineages (cex-1, cex-2, cex-4, and cex-5) and
six ce lineages (ce-1, ce-2, ce-5, ce-8, ce-9, and ce-10). The data
shown represent means of three independent determinations performed
with samples of different 50- to 65-day-old males plus standard
deviations. Note that four of six X-deficient lineages expressed
virtually no hepatic HBcAg whereas their renal HBcAg expression was the
same as that of the other lineages.
|
|
The low level of core gene expression in ce mice was not due to a
defect or a general silencing of the transgene.
One trivial
explanation for the virtual lack of core gene expression observed in
four of the six ce lineages was that the transgene might have been
rendered inactive due to a rearrangement which could have occurred
during the integration process. Alternatively, integration could have
taken place at unfavorable sites, resulting in the silencing of the
regulatory elements important for core gene expression.
In order to address these points, first the integrity of the transgenes
was examined in cex lineages cex-1 and cex-2 and ce
lineages ce-1,
ce-2, and ce-9 by amplifying the core promoter
region from genomic DNA
as described in Materials and Methods.
All PCR products showed the
expected sizes. The specificity of
the reaction products was controlled
by sequence analyses. These
experiments revealed that all transgenic
lineages investigated
lacked HBV nucleotide 2431 (nucleotide positions
are relative
to the HBc ATG with the A being nucleotide 1) upstream of
the
X ORF. Further analyses demonstrated that this point deletion
was
also present in the plasmids used for generation of the transgenic
mouse lines. However, since both the ce and the cex mice carried
the
same mutation, it could not explain the low level of core
gene
expression observed in the ce
animals.
To test whether there was a general inactivation of the transgene,
quantitative core protein analyses were performed with
the kidneys. It
is well documented that the core gene enhancer
is not strictly liver
specific in transgenic mice but rather is
active in a variety of
organs, in particular in the kidneys. As
is shown in Fig.
2B, a
significant level of core gene expression
could be found in the kidneys
of all cex and ce lineages. This
shows that the observed lack of
hepatic core protein expression
found in four ce lineages was not due
to a general silencing of
the
transgene.
Low levels of core protein expression in ce mice correlates with
strongly reduced core mRNA levels.
Since the pX protein can
transactivate the core gene in vitro, it appeared likely that the
strongly reduced core protein levels observed in four of the six ce
lineages was due to an impaired core gene transcription. To test this,
we performed Northern blot analyses with total liver RNA prepared from
all cex- or ce-line mice. As is shown in Fig.
3, lanes 1 to 5, a good expression of the
core gene transcript could be detected in livers of those cex and ce
mice which exhibited high-level HBcAg expression (mice from all four
X-intact cex lineages and from the X-defective lineage ce-1). In livers
of mice from the other five ce lines, only minute amounts of this
transcript could be detected (Fig. 3, lanes 6 to 10). The good
correlation between HBcAg and core mRNA expression shows that pX
probably does not exert a posttranscriptional effect on the core gene
products but rather might be required for efficient core gene
transcription.

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 3.
Hepatic core gene transcription of X-positive cex
lineages and X-negative ce lineages. Northern blots prepared with 25 µg of total liver RNA originating from mice of the four X-intact cex
lineages and the six X-defective ce-transgenic lineages were hybridized
with a HBV core-gene-specific (upper part) or GAPDH-specific (lower
part) probe. The 1.5-kb core-specific mRNA was well expressed in livers
from lineages with high-level HBcAg expression (all X-positive cex
lines and the X-defective lineage ce-1, lanes 1 to 5) but was virtually
not expressed in livers from lineages lacking or with low-level core
protein expression. X-negative ce lineages ce-2, ce-5, ce-8, ce-9, and
ce-10, lanes 6 to 10, respectively. B6, nontransgenic control.
|
|
The X-gene product can transactivate core gene expression in
transgenic livers.
As has been described above, four of the six
transgenic mouse lineages which lacked a functional X gene expressed
virtually no core mRNA in the liver. This allowed us to directly
address the question whether the X protein can exert a transactivating effect on the core gene in vivo. To date, this important issue has only
been analyzed in permanent cell lines which differ significantly from
fully differentiated hepatocytes. Transgenic mice of lineages ce-2 and
ce-9 were chosen for these experiments since these animals express
minimal amounts of core protein in the liver but exhibit high-level
HBcAg expression in the kidneys.
Hemizygous transgenic mice of lineages ce-2 and ce-9 were crossbred
with hemizygous animals from two mouse lineages expressing
a functional
HBV X gene under the transcriptional control of the
strong,
liver-specific MUP promoter (MUP-X-757 and MUP-X-760 mice
[
8]). As is depicted in Fig.
4, in all four breeding combinations
tested the double-transgenic (DT) mice exhibited significantly
(as
determined by the Wilcoxon test) increased HBcAg concentrations
in the
liver in comparison to their single-transgenic (ST) littermates.
The
enhancement factors of core protein expression were 18, 56,
16, and 331 for breeding combinations ce-2 × MUP-X-757, ce-9 ×
MUP-X-757, ce-2 × MUP-X-760, and ce-9 × MUP-X-760,
respectively.
To test whether there was any difference with respect to
hepatolobular
or subhepatocellular HBcAg expression between the
F
1(ce × MUP-X)
mice which express the X gene in
trans and the cex mice which
express this gene in
cis, liver sections were examined by immunohistochemistry.
The results are depicted in Fig.
5. In
the livers of both F
1(ce
× MUP-X) transgenic variants
tested, HBcAg-positive staining was
restricted to the nuclei of
hepatocytes located in the centrolobular
region of the hepatic lobule.
No HBcAg could be detected in the
periportal regions. An identical
expression pattern had previously
been detected in cex-transgenic
livers (
20). Hence, the HBcAg
expression pattern was
independent from the constructs employed
for transgene generation. As
expected, no staining could be observed
in sections derived from the
X-negative ce mice (data not shown).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 4.
Induction of HBcAg expression in livers of X-negative ce
mice by the MUP-X transgene. X-gene-defective ce-2 or ce-9 mice lacking
hepatic HBcAg expression were crossbred with MUP-X-757 or MUP-X-760
animals expressing high amounts of X mRNA in their livers
(8). HBcAg was quantitated in livers of ceST and
F1(ce × MUP-X) DT offspring. The data shown represent
mean values of at least five determinations performed with samples of
different 50- to 65-day-old mice plus standard deviations. In all four
breeding combinations tested, a significant difference of mean hepatic
HBcAg concentrations could be detected between ST and DT mice (as
determined by the Wilcoxon test).
|
|

View larger version (146K):
[in this window]
[in a new window]
|
FIG. 5.
Hepatolobular and subcellular distribution pattern of
HBcAg expression. Liver sections of F1(ce-2 × MUP-X-757) (upper panel) and F1(ce-9 × MUP-X-760)
(lower panel) mice were analyzed immunohistochemically with a
polyclonal antibody recognizing all epitopes of the core protein (final
magnification, ×490). HBcAg-specific staining was restricted to the
nuclei located in the centrolobular liver regions. A similar HBcAg
staining pattern had been previously observed in cex-transgenic mice
(20). No HBcAg staining was detectable in liver sections of
ce-2 or ce-9 ST controls (data not shown).
|
|
As is clear from these data, liver-specific core protein biosynthesis
could be restored in ce mice by the introduction of
an intact X gene.
To investigate whether this effect was due to
enhanced mRNA levels,
Northern blotting was performed with total
liver RNA prepared from ce
ST and F
1(ce × MUP-X) DT mice. As is
shown in Fig.
6, the expected core gene transcript
could be detected
in the DT (lanes 4, 5, 9, and 10) but not in the ST
(lanes 2,
3, 7, and 8) mice. The enhancement factors of core mRNA
expression
were 28 and 6 for breeding combinations ce-2 × MUP-X-757 and ce-2
× MUP-X-760, respectively. In fact,
trans expression of the X
gene resulted in mRNA levels which
were comparable to those found
in the cex mice which contain this gene
in a
cis arrangement.
These data clearly demonstrate that pX
has the potential to transactivate
core gene expression in vivo.

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of core gene transcription in livers of
X-negative ce mice by the MUP-X transgene. X-gene-defective ce-2 mice
lacking hepatic HBcAg expression were crossbred with X-mRNA-expressing
MUP-X-757 and MUP-X-760 animals, respectively. Core gene transcription
in livers of ce ST (lanes 2, 3, 7, and 8) and F1(ce × MUP-X) DT (lanes 4, 5, 9, and 11) offspring mice of various breeding
combinations was analyzed by Northern blotting using an HBV
core-gene-specific probe (upper part). Total liver RNA of
cex-1-transgenic mice (lanes 1 and 6) and nontransgenic B6 mice (lane
12) were analyzed in parallel as positive and negative controls,
respectively. A GAPDH-specific probe was used to equilibrate the RNA
(lower part). Note that with introduction of the MUP-X transgene,
expression of the core-gene-specific 1.5-kb transcript was induced in
livers of ce-transgenic mice.
|
|
 |
DISCUSSION |
The function of the HBV X-gene product during the viral life cycle
is unknown. The discoveries of Spandau and Lee (24), Zahm et
al. (29), Colgrove et al. (4), and many others
(22) have shown that pX can transactivate the transcription
of HBV-specific as well as many unrelated genes. However, since all
these studies were performed in vitro, the relevance to HBV
transcription in vivo has been unclear. There have been reports
suggesting that HBV mutants with defective X genes replicate after
transfection of cloned viral DNA into hepatoma cells (2, 14,
26), raising the question whether the X gene encodes an essential
viral protein at all. However, in all three studies it was observed
that gene expression and/or replication was reduced in hepatoma cells
transfected with HBV X mutants. More importantly, recently two groups
presented unequivocal evidence showing that a hepadnavirus which lacks
a functional X gene is noninfectious in vivo (3, 31). Since HBV infects only humans and chimpanzees, these experiments were carried
out with WHV. In several well-controlled studies both groups failed to
detect any sign of infection after the injection of WHV X-mutant DNA
into the liver, a method which otherwise reliably results in viremia.
It appears possible that the low number of genomes which enter a
hepatocyte during a normal infection, which in most cases is a single
copy, is not sufficiently well transcribed to allow for the initial
amplification of the covalently closed circular DNA which is a
prerequisite for long-term virus production. In transfection
experiments this limitation might be compensated by the large amount of
DNA which is usually taken up by the cells. Taken together, the
available data support two conclusions. Firstly, pX is essential for
the establishment of a hepadnavirus infection in vivo, and secondly, in
vitro systems may be of limited value for the analysis of pX function.
One major drawback of all in vivo systems is that it is usually not
possible to determine why a certain virus mutant is no longer
infectious. Consequently, while it could be shown in the aforementioned
studies that pX is definitely important for infectivity, its role
during the viral life cycle remained unresolved. To approach this
problem, we decided to analyze the transactivating properties of the
HBV X-gene product in an in vivo situation. These experiments were
performed with transgenic mice, which not only can be easily manipulated but also represent a good equivalent of a natural infection. In a previous study, we generated several transgenic mouse
lines using a construct containing the HBV X and core genes together
with all upstream sequences which are known to be important for their
expression. These lines consistently expressed high levels of HBc and
HBe protein as well as core specific mRNA in the liver, showing that
this construct was suitable to analyze the significance of pX for
hepatic core gene expression. To this end, we deleted the start codon
of the X gene and used this modified construct to generate six
additional transgenic lines.
As is shown here, the hepatic core protein expression pattern of the
X-deficient lineages was heterogenous. Two lineages exhibited low-level
and a high-level hepatic HBcAg expression, respectively, whereas four
of the lines expressed virtually no core protein in the liver. Why the
core gene was expressed in the livers of two of the lineages while it
was silent in the four other lines is unclear. The most probable
explanation is that in these lines integration of the transgene took
place at a favorable chromosomic site with a high basic expression
level, which is a general problem when gene expression is studied in
transgenic mice (10). However, statistical analysis of
hepatic core gene expression between all cex and ce lineages showed a
significant effect of X coexpression on the magnitude of core gene
expression in the liver, suggesting that pX has the potential to
increase core gene expression. These findings are reminiscent of data
published previously by Nagashima et al. (18). However, this
study suffered from the fact that only few X-deficient lineages and no
X-intact controls were examined, making the results difficult to interpret.
To directly test the hypothesis that HBx can enhance core gene
expression, we crossbred mice from two core-negative ce lines with mice
which expressed the X protein under foreign promoter control. Our data
convincingly demonstrate that core gene expression can be restored by
providing an active X gene in trans, and we believe that the
most plausible explanation for this result is that pX transactivated
the regulatory elements important for core gene transcription. In this
context it is important to mention that due to their structure the HBV
sequences which had been introduced into the transgenic lines cannot
give rise to replication-competent core particles. Thus, it can be
ruled out that the observed effect was due to a stimulated replication.
Our interpretation that the HBx is important for efficient hepatic HBV
gene expression in vivo is supported by observations which were made
during attempts to generate transgenic mice expressing a
replication-competent over-length HBV construct. When 1.1- and 1.2-genome-length constructs lacking the 5' X sequences were used to
produce transgenic mice, only low levels of HBV expression and
replication were observed (7). High-level HBV replication was only observed with a 1.3-genome-length construct that contained two
copies of the X transcription unit, one at each end. Whether this
finding was due to the position of the X gene or due to the amount of X
protein expressed is unclear. It is not possible to reliably detect the
X protein in organs by existing methods, e.g., Western blotting or
immunohistology. There are reports claiming successful detection of HBx
in vivo (13, 15, 25), but others had difficulty reproducing
these data (8, 19, 20). Therefore, it is not possible to
compare the amounts of X protein expressed in the 1.1-, 1.2-, or
1.3-genome-length or the MUP-X mice with the amount of X protein
expressed during a natural infection.
Taken together, the available data clearly demonstrates that pX has the
capacity to enhance the expression of the HBV core gene in vitro and in
vivo, supporting the hypothesis that the natural function of pX is to
enhance the transcription of the core gene during the viral life cycle.
 |
ACKNOWLEDGMENTS |
This work was supported by the Deutsche Forschungsgemeinschaft
(Re 1030/2-2 and Schl 270/1-3). The Heinrich Pette Institut is
financially supported by the Freie and Hansestadt Hamburg and the
Bundesministerium für Gesundheit.
We appreciate the excellent assistance of Johann Derksen, Nikolay
Derksen, Martina Fransewitz, Iris Gastrock-Balitsch, Susanne Knehr,
Timur Muratow, and Gabriele Spindler.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Virology, University of Ulm, Albert Einstein Allee 11, 89081 Ulm,
Germany. Phone: 49-731-502-3340. Fax: 49-731-502-3337. E-mail:
hans-juergen.schlicht{at}dezernat-6.uni-ulm.de.
 |
REFERENCES |
| 1.
|
Billet, O.,
G. Grimber,
M. Levrero,
K. Seye,
P. Briand, and V. Joulin.
1995.
In vivo activity of the hepatitis B virus core promoter: tissue specificity and temporal regulation.
J. Virol.
69:5912-5916[Abstract].
|
| 2.
|
Blum, H. E.,
Z. S. Zhang,
E. Galun,
F. von-Weizsacker,
B. Garner,
T. J. Liang, and J. R. Wands.
1992.
Hepatitis B virus X protein is not central to the viral life cycle in vitro.
J. Virol.
66:1223-1227[Abstract/Free Full Text].
|
| 3.
|
Chen, H.,
S. Kaneko,
R. Girones,
R. Anderson,
W. Hornbuckle,
B. Tennant,
P. Cote,
J. Gerin,
R. Purcell, and R. Miller.
1993.
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks.
J. Virol.
67:1218-1226[Abstract/Free Full Text].
|
| 4.
|
Colgrove, R.,
G. Simon, and D. Ganem.
1989.
Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication.
J. Virol.
63:4019-4026[Abstract/Free Full Text].
|
| 5.
|
Dandri, M.,
P. Schirmacher, and C. E. Rogler.
1996.
Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication.
J. Virol.
70:5246-5254[Abstract/Free Full Text].
|
| 6.
|
Ganem, D., and H. Varmus.
1987.
The molecular biology of the hepatitis B viruses.
Annu. Rev. Biochem.
56:651-693[Medline].
|
| 7.
|
Guidotti, L. G.,
B. Matzke,
H. Schaller, and F. V. Chisari.
1995.
High-level hepatitis B virus replication in transgenic mice.
J. Virol.
69:6158-6169[Abstract].
|
| 8.
|
Guidotti, L. G.,
B. Matzke,
C. Pasquinelli,
J. M. Shoenberger,
C. E. Rogler, and F. V. Chisari.
1996.
The hepatitis B virus precore protein inhibits HBV replication in transgenic mice.
J. Virol.
70:7056-7061[Abstract/Free Full Text].
|
| 9.
|
Guo, W.,
M. Chen,
T. S. Yen, and J. H. Ou.
1993.
Hepatocyte-specific expression of the hepatitis B virus core promoter depends on both positive and negative regulation.
Mol. Cell. Biol.
13:443-448[Abstract/Free Full Text].
|
| 10.
|
Hammer, R. E.,
R. Krumlauf,
S. A. Camper,
R. L. Brinster, and S. M. Tilghman.
1987.
Diversity of alpha-fetoprotein gene expression in mice is generated by a combination of separate enhancer elements.
Science
235:53-58[Abstract/Free Full Text].
|
| 11.
|
Hsu, S.,
L. Raine, and H. Fanger.
1981.
Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures.
J. Histochem. Cytochem.
29:577-580[Abstract].
|
| 12.
|
Hu, K. Q., and A. Siddiqui.
1991.
Regulation of the hepatitis B virus gene expression by the enhancer element I.
Virology
181:721-726[Medline].
|
| 13.
|
Kim, C. M.,
K. Koike,
I. Saito,
T. Miyamura, and G. Jay.
1991.
HBx gene of hepatitis B virus induces liver cancer in transgenic mice.
Nature
351:317-320[Medline].
|
| 14.
|
Koike, K.,
Y. Shirakata,
K. Yaginuma,
M. Arii,
S. Takada,
I. Nakamura,
Y. Hayashi,
M. Kawada, and M. Kobayashi.
1989.
Oncogenic potential of hepatitis B virus.
Mol. Biol. Med.
6:151-160[Medline].
|
| 15.
|
Lee, T. H.,
M. J. Finegold,
R. F. Shen,
J. L. DeMayo,
S. L. Woo, and J. S. Butel.
1990.
Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice.
J. Virol.
64:5939-5947[Abstract/Free Full Text].
|
| 16.
|
Levrero, M.,
M. Stemler,
C. Pasquinelli,
A. Alberti,
O. Jean-Jean,
A. Franco,
C. Balsano,
D. Diop,
C. Brechot,
M. Melegari, et al.
1991.
Significance of anti-HBx antibodies in hepatitis B virus infection.
Hepatology
13:143-149[Medline].
|
| 17.
|
Miller, R. H., and W. S. Robinson.
1986.
Common evolutionary origin of hepatitis B virus and retroviruses.
Proc. Natl. Acad. Sci. USA
83:2531-2535[Abstract/Free Full Text].
|
| 18.
|
Nagashima, H.,
M. Imai, and H. Iwakura.
1993.
Aberrant tissue specific expression of the transgene in transgenic mice that carry the hepatitis B virus genome defective in the X gene.
Arch. Virol.
132:381-397[Medline].
|
| 19.
|
Pfaff, E.,
J. Salfeld,
K. Gmelin,
H. Schaller, and L. Theilmann.
1987.
Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera.
Virology
158:456-460[Medline].
|
| 20.
|
Reifenberg, K.,
J. Löhler,
H. P. Pudollek,
E. Schmitteckert,
G. Spindler,
J. Köck, and H. J. Schlicht.
1997.
Long term expression of the hepatitis B virus core e- and X-proteins does not cause organ pathology in transgenic mice.
J. Hepatol.
26:119-130[Medline].
|
| 21.
|
Reifenberg, K.,
T. Deutschle,
J. Wild,
R. Hanano,
I. Gastrock-Balitsch,
R. Schirmbeck, and H. J. Schlicht.
1998.
The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero.
Virology
243:45-53[Medline].
|
| 22.
|
Rossner, M.
1992.
The hepatitis B virus x-gene product: a promiscuous transcriptional activator.
J. Med. Virol.
36:101-117[Medline].
|
| 23.
|
Schlicht, H. J., and H. Schaller.
1989.
The secretory core protein of human hepatitis B virus is expressed on the cell surface.
J. Virol.
63:5399-5404[Abstract/Free Full Text].
|
| 24.
|
Spandau, D. F., and C. H. Lee.
1988.
trans-Activation of viral enhancers by the hepatitis B virus X protein.
J. Virol.
62:427-434[Abstract/Free Full Text].
|
| 25.
|
Su, Q.,
C. H. Schroder,
W. J. Hofmann,
G. Otto,
R. Pichlmayr, and P. Bannasch.
1998.
Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas.
Hepatology
27:1109-1120[Medline].
|
| 26.
|
Yaginuma, K.,
Y. Shirakata,
M. Kobayashi, and K. Koike.
1987.
Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA.
Proc. Natl. Acad. Sci. USA
84:2678-2682[Abstract/Free Full Text].
|
| 27.
|
Yaginuma, K.,
I. Nakamura,
S. Takada, and K. Koike.
1993.
A transcription initiation site for the hepatitis B virus X gene is directed by the promoter-binding protein.
J. Virol.
67:2559-2565[Abstract/Free Full Text].
|
| 28.
|
Yuh, C., and L. Ting.
1990.
The genome of hepatitis B virus contains a second enhancer: cooperation of two elements within this enhancer is required for its function.
J. Virol.
64:4281-4287[Abstract/Free Full Text].
|
| 29.
|
Zahm, P.,
P. H. Hofschneider, and R. Koshy.
1988.
The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis.
Oncogene
3:169-177[Medline].
|
| 30.
|
Zhang, P.,
A. Raney, and A. McLachlan.
1992.
Characterization of the hepatitis B virus X- and nucleocapsid gene transcriptional regulatory elements.
Virology
191:31-41[Medline].
|
| 31.
|
Zoulim, F.,
J. Saputelli, and C. Seeger.
1994.
Woodchuck hepatitis virus X protein is required for viral infection in vivo.
J. Virol.
68:2026-2030[Abstract/Free Full Text].
|
Journal of Virology, December 1999, p. 10399-10405, Vol. 73, No. 12
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Tang, H., Delgermaa, L., Huang, F., Oishi, N., Liu, L., He, F., Zhao, L., Murakami, S.
(2005). The Transcriptional Transactivation Function of HBx Protein Is Important for Its Augmentation Role in Hepatitis B Virus Replication. J. Virol.
79: 5548-5556
[Abstract]
[Full Text]
-
Bouchard, M. J., Schneider, R. J.
(2004). The Enigmatic X Gene of Hepatitis B Virus. J. Virol.
78: 12725-12734
[Full Text]
-
Kim, J.-H., Kang, S., Kim, J., Ahn, B.-Y.
(2003). Hepatitis B Virus Core Protein Stimulates the Proteasome-Mediated Degradation of Viral X Protein. J. Virol.
77: 7166-7173
[Abstract]
[Full Text]
-
Reifenberg, K., Nusser, P., Lohler, J., Spindler, G., Kuhn, C., von Weizsacker, F., Kock, J.
(2002). Virus replication and virion export in X-deficient hepatitis B virus transgenic mice. J. Gen. Virol.
83: 991-996
[Abstract]
[Full Text]
-
Xu, Z., Yen, T. S. B., Wu, L., Madden, C. R., Tan, W., Slagle, B. L., Ou, J.-h.
(2002). Enhancement of Hepatitis B Virus Replication by Its X Protein in Transgenic Mice. J. Virol.
76: 2579-2584
[Abstract]
[Full Text]
-
Nijhara, R., Jana, S. S., Goswami, S. K., Rana, A., Majumdar, S. S., Kumar, V., Sarkar, D. P.
(2001). Sustained Activation of Mitogen-Activated Protein Kinases and Activator Protein 1 by the Hepatitis B Virus X Protein in Mouse Hepatocytes In Vivo. J. Virol.
75: 10348-10358
[Abstract]
[Full Text]
-
Henkler, F., Hoare, J., Waseem, N., Goldin, R. D., McGarvey, M. J., Koshy, R., King, I. A.
(2001). Intracellular localization of the hepatitis B virus HBx protein. J. Gen. Virol.
82: 871-882
[Abstract]
[Full Text]